bluuebunny/crossref_metadata_2025 huggingface dataset:
Figure S4 from Peripheral Blood TCR Repertoire Profiling May Facilitate Patient Stratification for Immunotherapy against Melanoma
Authors: Hogan Sabrina A. , Courtier Anaïs , Cheng Phil F. , Jaberg-Bentele Nicoletta F. , Goldinger Simone M. , Manuel Manuarii , Perez Solène , Plantier Nadia , Mouret Jean-François , Nguyen-Kim Thi Dan Linh , Raaijmakers Marieke I.G. , Kvistborg Pia , Pasqual Nicolas , Haanen John B.A.G. , Dummer Reinhard , Levesque Mitchell P.
Published: April 2023

3D representation of the TCR diversity. Each peak represents a rearrangement between a given V gene family and a J segment. X axis: TRBV, y axis: TRBJ, z axis relative intensity. The table shows the top 10 rearrangements, listed in decreasing order of contribution to the global repertoire. Contribution is calculated based on the ratio between individual rearrangement intensity and the sum of all rearrangements intensities. A) Immune maps of the patients eventually responding to anti-PD1 therapy (PD and CR). B) Immune maps of the patients who eventually did not respond to anti-PD1 therapy (PD).
Figure S1 from PI3Kγ Activates Integrin α4 and Promotes Immune Suppressive Myeloid Cell Polarization during Tumor Progression
Authors: Foubert Philippe , Kaneda Megan M. , Varner Judith A.
Published: April 2023

Tumor growth curves
Figure S1 from Peripheral Blood TCR Repertoire Profiling May Facilitate Patient Stratification for Immunotherapy against Melanoma
Authors: Hogan Sabrina A. , Courtier Anaïs , Cheng Phil F. , Jaberg-Bentele Nicoletta F. , Goldinger Simone M. , Manuel Manuarii , Perez Solène , Plantier Nadia , Mouret Jean-François , Nguyen-Kim Thi Dan Linh , Raaijmakers Marieke I.G. , Kvistborg Pia , Pasqual Nicolas , Haanen John B.A.G. , Dummer Reinhard , Levesque Mitchell P.
Published: April 2023

Effect of previous treatment on variables tested in our model. (Kruskal-Wallis test)
Figure S1 from Rapid Construction of Antitumor T-cell Receptor Vectors from Frozen Tumors for Engineered T-cell Therapy
Authors: Tsuji Takemasa , Yoneda Akira , Matsuzaki Junko , Miliotto Anthony , Ryan Courtney , Koya Richard C. , Odunsi Kunle
Published: April 2023

Fig. S1 describes about the destination plasmid.
Supplementary Figures 1 - 4 from Escalating Regulation of 5T4-Specific IFN-γ+ CD4+ T Cells Distinguishes Colorectal Cancer Patients from Healthy Controls and Provides a Target for In Vivo Therapy
Authors: Scurr Martin , Bloom Anja , Pembroke Tom , Srinivasan Rohit , Brown Clare , Smart Kathryn , Bridgeman Hayley , Davies Mike , Hargest Rachel , Phillips Simon , Christian Adam , Hockey Tom , Gallimore Awen , Godkin Andrew
Published: April 2023

PDF file - 10925K, S. Fig. 1. Cultured 5T4-specific CD4+ T cells can be cloned from CRC patients (A) and healthy donors (B). S. Fig. 2. A comparison of 5T4 responses and age amongst CRC patients. S. Fig. 3. 5T4 Immunohistochemistry staining of frozen sections. S. Fig. 4. CT scans demonstrating the growth of a single metastatic lung lesion in a patient who did not respond to low-dose cyclophosphamide treatment.
Supplementary Figure 1 from Polyamine-Blocking Therapy Reverses Immunosuppression in the Tumor Microenvironment
Authors: Hayes Candace S. , Shicora Allyson C. , Keough Martin P. , Snook Adam E. , Burns Mark R. , Gilmour Susan K.
Published: April 2023

PDF file - 797K, Increased macrophage infiltration in Ker/Ras tumors from mice treated with DFMO and AMXT 1501.
Supplementary Figure Legend from Combined Targeting of Costimulatory (OX40) and Coinhibitory (CTLA-4) Pathways Elicits Potent Effector T Cells Capable of Driving Robust Antitumor Immunity
Authors: Redmond William L. , Linch Stefanie N. , Kasiewicz Melissa J.
Published: April 2023

PDF file - 74K
Supplementary Figure 3 from Combined Targeting of Costimulatory (OX40) and Coinhibitory (CTLA-4) Pathways Elicits Potent Effector T Cells Capable of Driving Robust Antitumor Immunity
Authors: Redmond William L. , Linch Stefanie N. , Kasiewicz Melissa J.
Published: April 2023

PDF file - 34K, Co-expression of T-bet and Gata-3 in CD4 T cells following anti-OX40/anti-CTLA-4 therapy.
Supplementary Figure 1 from Combined Targeting of Costimulatory (OX40) and Coinhibitory (CTLA-4) Pathways Elicits Potent Effector T Cells Capable of Driving Robust Antitumor Immunity
Authors: Redmond William L. , Linch Stefanie N. , Kasiewicz Melissa J.
Published: April 2023

PDF file - 63K, Total cell numbers following combined anti-OX40/anti-CTLA-4 immunotherapy.
Supplementary Tables and Figures S1-S8; Material and Methods from Functional TCR Retrieval from Single Antigen-Specific Human T Cells Reveals Multiple Novel Epitopes
Authors: Simon Petra , Omokoko Tana A. , Breitkreuz Andrea , Hebich Lisa , Kreiter Sebastian , Attig Sebastian , Konur Abdo , Britten Cedrik M. , Paret Claudia , Dhaene Karl , Türeci Özlem , Sahin Ugur
Published: April 2023

Supplementary Table S1. Primers used in this study. Supplementary Table S2. A/B Coverage of TCR-α (A) and TCR-β (B) variable genes with clonotype-specific primers. Supplementary Table S3. Characteristics of cloned TCRs. Supplementary Figure S4. Flow cytometric sorting of pp65-specific CD8+ T cells from CMV-seropositive donor ID3 after one week of expansion. Supplementary Table S5. Synthetic peptides used in this study. Supplementary Figure S6. Functionality of TCRCD8-NY#5 in CD4+ and CD8+ T cells. Supplementary Figure S7. Functionality of NY-ESO-1-specific CD4-TCRs in CD8+ T cells. Supplementary Table S8. HLA haplotypes from healthy donors and NSCLC patients. Supplementary Methods. Detailed materials and methods.
Supplementary Methods and Figure Legend from Lysophosphatidic Acid Inhibits CD8 T-cell Activation and Control of Tumor Progression
Authors: Oda Shannon K. , Strauch Pamela , Fujiwara Yuko , Al-Shami Amin , Oravecz Tamas , Tigyi Gabor , Pelanda Roberta , Torres Raul M.
Published: April 2023

PDF file - 96K
Supplementary Figures 1 - 4 from Lysophosphatidic Acid Inhibits CD8 T-cell Activation and Control of Tumor Progression
Authors: Oda Shannon K. , Strauch Pamela , Fujiwara Yuko , Al-Shami Amin , Oravecz Tamas , Tigyi Gabor , Pelanda Roberta , Torres Raul M.
Published: April 2023

PDF file - 75K, Supplementary Figure S1. Intracellular calcium mobilization was assessed in CD8+ T cells stimulated with 10 g/mL anti-CD3 with or without 20 M LPA (thin and bold lines, respectively). 20 M LPA treatment in the absence of TCR stimulation is shown in gray line. Supplementary Figure S2. LPA treatment inhibits CD8+ T cell activation with suboptimal TCR stimulation. C57BL/6 splenocytes were cultured for 24 hours with (center and right histograms) or without (left histogram) indicated plate-bound anti-CD3 and 1 g/mL soluble anti-CD28, in the presence (blue and green lines) or absence of LPA (red line, gray filled). Data shown is gated on CD8+ T cells. Representative of 2 independent experiments. Supplementary Figure S3. OTP pretreatment of APC does not affect antigen presentation. Erythrocyte-lysed splenocytes from a T cell-deficient mouse (TCR-/-) were pulsed with SIINFEKL peptide in the presence (black) or absence (white) of OTP, washed, and used to stimulate purified CD8+ OT-I T cells in the presence or absence of OTP. Supplementary Figure S4. Generation and characterization of LPA5-/- mice. A, Schematic diagram of Lpar5 targeted deletion. A portion of the Lpar5 gene was replaced with a LacZ/neo selection cassette. B, PCR genotyping displaying wild-type and mutant Lpar5. Primers are indicated in Supp. Fig. 4A. C, Southern hybridization indicating the proper targeting event in ESC clones. D, Proportions of T cells and CD4+ and CD8+ T cell subsets in spleens of LPA5+/+ and LPA5-/- mice.
Supplementary Figure 7 from Tumoral Immune Suppression by Macrophages Expressing Fibroblast Activation Protein-α and Heme Oxygenase-1
Authors: Arnold James N. , Magiera Lukasz , Kraman Matthew , Fearon Douglas T.
Published: April 2023

PDF file - 25K, Effects of HO inhibition on tumoral immune cells.
Supplementary Figure 5 from Tumoral Immune Suppression by Macrophages Expressing Fibroblast Activation Protein-α and Heme Oxygenase-1
Authors: Arnold James N. , Magiera Lukasz , Kraman Matthew , Fearon Douglas T.
Published: April 2023

PDF file - 13K, Assessment of HO-1 and HO-2 expression in LL2/OVA tumors.
Supplementary Figure 2 from Influenza Virus Infection Elicits Protective Antibodies and T Cells Specific for Host Cell Antigens Also Expressed as Tumor-Associated Antigens: A New View of Cancer Immunosurveillance
Authors: Iheagwara Uzoma K. , Beatty Pamela L. , Van Phu T. , Ross Ted M. , Minden Jonathan S. , Finn Olivera J.
Published: April 2023

PDF file - 1448K, Supplementary Figure S2: Example gating strategy of antigen specific CD3+CD8+Dimer-X+ T cells.
Supplementary Figure 3 from Myeloid-Derived Suppressor Cells Attenuate TH1 Development through IL-6 Production to Promote Tumor Progression
Authors: Tsukamoto Hirotake , Nishikata Ryutaro , Senju Satoru , Nishimura Yasuharu
Published: April 2023

PDF file - 920K, The effect of MDSC-derived IL-6 on Th1 differentiation.
Supplementary Figure 1 from Myeloid-Derived Suppressor Cells Attenuate TH1 Development through IL-6 Production to Promote Tumor Progression
Authors: Tsukamoto Hirotake , Nishikata Ryutaro , Senju Satoru , Nishimura Yasuharu
Published: April 2023

PDF file - 830K, Representative plots showing IFN-γproduction in tumor-specific CD4+ T cells.
Supplementary Figure Legend and Table 1 from Enhancement of Tumor-Reactive Cytotoxic CD4+ T-cell Responses after Ipilimumab Treatment in Four Advanced Melanoma Patients
Authors: Kitano Shigehisa , Tsuji Takemasa , Liu Caillian , Hirschhorn-Cymerman Daniel , Kyi Chrisann , Mu Zhenyu , Allison James P. , Gnjatic Sacha , Yuan Jianda D. , Wolchok Jedd D.
Published: April 2023

PDF file - 106K, Supplemental Table 1 Summary of NY-ESO-1 Immune responses.
Supplementary Table 2 from Immune Impact Induced by PROSTVAC (PSA-TRICOM), a Therapeutic Vaccine for Prostate Cancer
Authors: Gulley James L. , Madan Ravi A. , Tsang Kwong Y. , Jochems Caroline , Marté Jennifer L. , Farsaci Benedetto , Tucker Jo A. , Hodge James W. , Liewehr David J. , Steinberg Seth M. , Heery Christopher R. , Schlom Jeffrey
Published: April 2023

XLSX file - 32K, Adverse events.
Supplemental Table 2 from A Blueprint to Advance Colorectal Cancer Immunotherapies
Authors: Le Dung T. , Hubbard-Lucey Vanessa M. , Morse Michael A. , Heery Christopher R. , Dwyer Andrea , Marsilje Thomas H. , Brodsky Arthur N. , Chan Emily , Deming Dustin A. , Diaz Luis A. , Fridman Wolf H. , Goldberg Richard M. , Hamilton Stanley R. , Housseau Franck , Jaffee Elizabeth M. , Kang S. Peter , Krishnamurthi Smitha S. , Lieu Christopher H. , Messersmith Wells , Sears Cynthia L. , Segal Neil H. , Yang Arvin , Moss Rebecca A. , Cha Edward , O'Donnell-Tormey Jill , Roach Nancy , Davis Anjelica Q. , McAbee Keavy , Worrall Sharyn , Benson Al B.
Published: April 2023

S2. Policy and Infrastructure driven solutions noted for support of immunology work.
Supplemental Table 1 from A Blueprint to Advance Colorectal Cancer Immunotherapies
Authors: Le Dung T. , Hubbard-Lucey Vanessa M. , Morse Michael A. , Heery Christopher R. , Dwyer Andrea , Marsilje Thomas H. , Brodsky Arthur N. , Chan Emily , Deming Dustin A. , Diaz Luis A. , Fridman Wolf H. , Goldberg Richard M. , Hamilton Stanley R. , Housseau Franck , Jaffee Elizabeth M. , Kang S. Peter , Krishnamurthi Smitha S. , Lieu Christopher H. , Messersmith Wells , Sears Cynthia L. , Segal Neil H. , Yang Arvin , Moss Rebecca A. , Cha Edward , O'Donnell-Tormey Jill , Roach Nancy , Davis Anjelica Q. , McAbee Keavy , Worrall Sharyn , Benson Al B.
Published: April 2023

S1. Therapeutic strategies and corresponding laboratory tests.
Supplementary Figures 1 through 5 from Vaccines Combined with Immune Checkpoint Antibodies Promote Cytotoxic T-cell Activity and Tumor Eradication
Authors: Ali Omar A. , Lewin Sarah A. , Dranoff Glenn , Mooney David J.
Published: April 2023

Figure S1 - Treatment of tumor bearing mice with anti-CTLA-4 and Anti-PD1 antibodies. Figure S2 - The effects of stopping antibody treatment after PLG vaccination on tumor growth. Figure S3 - The ratio of CD3(+)CD8(+) T cells to CD3(+)FoxP3(+) T regulatory cells isolated from the B16 tumors of untreated mice (Control) and mice treated with PLG vaccines alone (Vax) or in combination with anti-PD-1 (+PD-1) and anti-CTLA-4 (+CTLA-4) antibodies. Figure S4 - Combining multiple checkpoint blockades with PLG cancer vaccines. Figure S5 - Effector and regulatory T cell activity in lymph node that drains vaccine site.
Supplementary Figures S3 to S6 from Tn-MUC1 DC Vaccination of Rhesus Macaques and a Phase I/II Trial in Patients with Nonmetastatic Castrate-Resistant Prostate Cancer
Authors: Scheid Elizabeth , Major Pierre , Bergeron Alain , Finn Olivera J. , Salter Russell D. , Eady Robin , Yassine-Diab Bader , Favre David , Peretz Yoav , Landry Claire , Hotte Sebastien , Mukherjee Som D. , Dekaban Gregory A. , Fink Corby , Foster Paula J. , Gaudet Jeffery , Gariepy Jean , Sekaly Rafick-Pierre , Lacombe Louis , Fradet Yves , Foley Ronan
Published: April 2023

Figure S3: Representative gating scheme illustrating the functional subsets induced within the memory CD4+ and CD8+ T cell pools following the stimulation of PBMCs with NP-DCs, KLH-DCs and Tn-MUC1-DCs.; Figure S4: Frequency of KLH-specific cytokine-secreting memory CD4+ T cell subsets and CD8+ T cell subsets at baseline, < 2 months, and > 6 months following vaccination.; Figure S5 Frequency of Tn-MUC1-specific cytokine-secreting memory CD4+ T cell subsets (A) and CD8+ T cell subsets (B) at baseline, < 2 months, and > 6 months following vaccination.; Figure S6: Representative gating scheme illustrating the Treg subsets induced within the CD4+ T cell pool.
Supplementary Figure S2 from Tn-MUC1 DC Vaccination of Rhesus Macaques and a Phase I/II Trial in Patients with Nonmetastatic Castrate-Resistant Prostate Cancer
Authors: Scheid Elizabeth , Major Pierre , Bergeron Alain , Finn Olivera J. , Salter Russell D. , Eady Robin , Yassine-Diab Bader , Favre David , Peretz Yoav , Landry Claire , Hotte Sebastien , Mukherjee Som D. , Dekaban Gregory A. , Fink Corby , Foster Paula J. , Gaudet Jeffery , Gariepy Jean , Sekaly Rafick-Pierre , Lacombe Louis , Fradet Yves , Foley Ronan
Published: April 2023

[19F]-Fluorine cellular MRI detection of the migration of Cell Sense-labeled DCs in the popliteal lymph node of a nude Balb/c mice 48h following injection.
Supplementary Table S3 from IFNγ Induces DNA Methylation–Silenced GPR109A Expression via pSTAT1/p300 and H3K18 Acetylation in Colon Cancer
Authors: Bardhan Kankana , Paschall Amy V. , Yang Dafeng , Chen May R. , Simon Priscilla S. , Bhutia Yangzom D. , Martin Pamela M. , Thangaraju Muthusamy , Browning Darren D. , Ganapathy Vadivel , Heaton Christopher M. , Gu Keni , Lee Jeffrey R. , Liu Kebin
Published: April 2023

Table S3. Differential expression of inflammatory genes in human colon carcinoma
Supplementary Table 1 from Long-term Complete Remission Following Radiosurgery and Immunotherapy in a Melanoma Patient with Brain Metastasis: Immunologic Correlates
Authors: Karbach Julia , Gnjatic Sacha , Biskamp Melina , Atmaca Akin , Weidmann Eckhart , Brandt Kathrin , Wahle Claudia , Bernhard Helga , Knuth Alexander , Jäger Elke
Published: April 2023

XLSX file - 31K, Antigen expression of several melanoma metastases by RT-PCR.
Supplementary Table S2 from IFNγ Induces DNA Methylation–Silenced GPR109A Expression via pSTAT1/p300 and H3K18 Acetylation in Colon Cancer
Authors: Bardhan Kankana , Paschall Amy V. , Yang Dafeng , Chen May R. , Simon Priscilla S. , Bhutia Yangzom D. , Martin Pamela M. , Thangaraju Muthusamy , Browning Darren D. , Ganapathy Vadivel , Heaton Christopher M. , Gu Keni , Lee Jeffrey R. , Liu Kebin
Published: April 2023

Table S2. Scores of CD4+ and CD8+ peritumoral lymphocytes, and tumor GPR109A protein levels in 10 human CRC specimens.
Supplementary Table S1 from IFNγ Induces DNA Methylation–Silenced GPR109A Expression via pSTAT1/p300 and H3K18 Acetylation in Colon Cancer
Authors: Bardhan Kankana , Paschall Amy V. , Yang Dafeng , Chen May R. , Simon Priscilla S. , Bhutia Yangzom D. , Martin Pamela M. , Thangaraju Muthusamy , Browning Darren D. , Ganapathy Vadivel , Heaton Christopher M. , Gu Keni , Lee Jeffrey R. , Liu Kebin
Published: April 2023

Table S1. Oligo sequences
Supplementary Figure 2 from Effector Regulatory T Cells Reflect the Equilibrium between Antitumor Immunity and Autoimmunity in Adult T-cell Leukemia
Authors: Ureshino Hiroshi , Shindo Takero , Nishikawa Hiroyoshi , Watanabe Nobukazu , Watanabe Eri , Satoh Natsuko , Kitaura Kazutaka , Kitamura Hiroaki , Doi Kazuko , Nagase Kotaro , Kimura Hiromi , Samukawa Makoto , Kusunoki Susumu , Miyahara Masaharu , Shin-I Tadasu , Suzuki Ryuji , Sakaguchi Shimon , Kimura Shinya
Published: April 2023

Histopathological findings of the skin rash and the brain (Case 2)
Supplementary Figure S3 from IFNγ Induces DNA Methylation–Silenced GPR109A Expression via pSTAT1/p300 and H3K18 Acetylation in Colon Cancer
Authors: Bardhan Kankana , Paschall Amy V. , Yang Dafeng , Chen May R. , Simon Priscilla S. , Bhutia Yangzom D. , Martin Pamela M. , Thangaraju Muthusamy , Browning Darren D. , Ganapathy Vadivel , Heaton Christopher M. , Gu Keni , Lee Jeffrey R. , Liu Kebin
Published: April 2023

Figure S3: Immunohistochemical staining of GPR109A protein level in colon carcinoma tissues from 10 patients. The brown color indicates specific GPR109A protein staining.
Supplementary Figures 1 through 4 from Established T Cell–Inflamed Tumors Rejected after Adaptive Resistance Was Reversed by Combination STING Activation and PD-1 Pathway Blockade
Authors: Moore Ellen , Clavijo Paul E. , Davis Ruth , Cash Harrison , Van Waes Carter , Kim Young , Allen Clint
Published: April 2023

Details additional immune correlative changes in treated MOC1 tumors, immune correlative changes in treated MOC2 tumors, and provides validation of the in vivo CTL assay.
Supplemental Figure S1 from Checkpoint Blockade Immunotherapy Relies on T-bet but Not Eomes to Induce Effector Function in Tumor-Infiltrating CD8+ T Cells
Authors: Berrien-Elliott Melissa M. , Yuan Jinyun , Swier Lauryn E. , Jackson Stephanie R. , Chen Collin L. , Donlin Maureen J. , Teague Ryan M.
Published: April 2023

Heat map of 53 selected genes differentially expressed in tolerant versus immune CD8+ T cells.
Supplementary Figure legends from Long-term Survival and Clinical Benefit from Adoptive T-cell Transfer in Stage IV Melanoma Patients Is Determined by a Four-Parameter Tumor Immune Signature
Authors: Melief Sara M. , Visconti Valeria V. , Visser Marten , van Diepen Merel , Kapiteijn Ellen H.W. , van den Berg Joost H. , Haanen John B.A.G. , Smit Vincent T.H.B.M. , Oosting Jan , van der Burg Sjoerd H. , Verdegaal Els M.E.
Published: April 2023

Legends for supplementary Figure 1 through 5
Supplementary Table 1 from PD-1+Tim-3+ CD8+ T Lymphocytes Display Varied Degrees of Functional Exhaustion in Patients with Regionally Metastatic Differentiated Thyroid Cancer
Authors: Severson Jill J. , Serracino Hilary S. , Mateescu Valerica , Raeburn Christopher D. , McIntyre Robert C. , Sams Sharon B. , Haugen Bryan R. , French Jena D.
Published: April 2023

Supplementary Table 1. Galectin-9 staining in TILN. The level of staining is displayed as intensity; area of positive staining; Allred score. Rabbit IgG controls scored as negative. nLN = normal lymph node. Patients categorized as PD-1+Tim-3+ are highlighted in grey.
Supplementary Figure 7 from Adenosine Receptor 2A Blockade Increases the Efficacy of Anti–PD-1 through Enhanced Antitumor T-cell Responses
Authors: Beavis Paul A. , Milenkovski Nicole , Henderson Melissa A. , John Liza B. , Allard Bertrand , Loi Sherene , Kershaw Michael H. , Stagg John , Darcy Phillip K.
Published: April 2023

This supplementray Figure shows the expression of IFNy and Granzyme B on tumor-infiltrating lymphocytes 7 days post anti-PD-1/ anti-PD-1/A2A blockade.
Supplementary Figure 4 from Adenosine Receptor 2A Blockade Increases the Efficacy of Anti–PD-1 through Enhanced Antitumor T-cell Responses
Authors: Beavis Paul A. , Milenkovski Nicole , Henderson Melissa A. , John Liza B. , Allard Bertrand , Loi Sherene , Kershaw Michael H. , Stagg John , Darcy Phillip K.
Published: April 2023

This supplementary figure shows the expression of PD-1 on tumor infiltrating immune subsets.
Supplementary Table S1, Figures S1 - S12 from Tumor-Derived α-Fetoprotein Directly Drives Human Natural Killer–Cell Activation and Subsequent Cell Death
Authors: Vujanovic Lazar , Stahl Elizabeth C. , Pardee Angela D. , Geller David A. , Tsung Allan , Watkins Simon C. , Gibson Gregory A. , Storkus Walter J. , Butterfield Lisa H.
Published: April 2023

Supplementary Table S1. Donor median secretion levels (pg/ml). Supplementary Figure S1. Evaluation of AFP internalization mechanism. Supplementary Figure S2. nAFP and tAFP enhance IL-2-induced NK cell activation in a dosedependent manner. Supplementary Figure S3. Intracellular IL-6 and IL-1β staining of NK cells. Supplementary Figure S4. IL-1β and IL-6 production by CD3+ and CD14+ cell contaminants. Supplementary Figure S5. nAFP and tAFP stimulations induce a pro-inflammatory, IL-2-hyperresponsive activation profile in NK-cells. Supplementary Figure S6. Confirmation of protein observations by NanoString single molecule imaging. Supplementary Figure S7. nAFP and tAFP stimulations induce a pro-inflammatory, IL-2-hyperresponsive activation profile in NK-cells. Supplementary Figure S8. nAFP and tAFP stimulations enhance NK cell-mediated tumor killing. Supplementary Figure S9. FACS analysis strategy for evaluating internalized AFP by NK cells. Supplementary Figure S10. Gating strategy used to evaluate NK cell viability in long-term cultures. Supplementary Figure S11. tAFP inhibits proliferation and promotes the death of NK cells in extended cultures. Supplementary Figure S12. RP-HPLC Fractionation of tAFP and its cargo.
Supplementary Figure 3 from Adenovirus Improves the Efficacy of Adoptive T-cell Therapy by Recruiting Immune Cells to and Promoting Their Activity at the Tumor
Authors: Tähtinen Siri , Grönberg-Vähä-Koskela Susanna , Lumen Dave , Merisalo-Soikkeli Maiju , Siurala Mikko , Airaksinen Anu J. , Vähä-Koskela Markus , Hemminki Akseli
Published: April 2023

Supplementary Figure S3: SPECT/CT imaging experiment to study biodistribution and trafficking of radiolabeled OT-I cells in B16.OVA bearing mice.
Supplementary Figure 1 from Adenovirus Improves the Efficacy of Adoptive T-cell Therapy by Recruiting Immune Cells to and Promoting Their Activity at the Tumor
Authors: Tähtinen Siri , Grönberg-Vähä-Koskela Susanna , Lumen Dave , Merisalo-Soikkeli Maiju , Siurala Mikko , Airaksinen Anu J. , Vähä-Koskela Markus , Hemminki Akseli
Published: April 2023

Supplementary Figure S1: Expression levels of intratumoral chemokines following adenovirus injections.
Supplemental Figure Legends from The Inhibitory Signaling Receptor Protocadherin-18 Regulates Tumor-Infiltrating CD8+ T-cell Function
Authors: Frey Alan B.
Published: April 2023

S1. Pcdh 18 is expressed in anti-L. monocytogenes (SIINFEKL-specific) CD8+ T cells. S2. Table of TIL ISR from gene array. S3. Expression of immune cell molecules in wild-type and pcdh 18-/- CD8+ T spleen cells. S4. Antibody blockade of PD-1 or pcdh18 in wild type mice. S5. IFNï�§ secretion by human CD8+ naive T cells is not impacted by anti-pcdh18 amino terminal-specific Ab, but is enhanced in CD8+ effector memory cells. Human central memory T cells express pcdh18 coincident with in vitro conversion to effector memory cells. S6. Human central memory T cells express pcdh18 coincident with in vitro conversion to effector memory cells.
Supplementary Figure 1 from Stereotactic Radiation Therapy Augments Antigen-Specific PD-1–Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen
Authors: Sharabi Andrew B. , Nirschl Christopher J. , Kochel Christina M. , Nirschl Thomas R. , Francica Brian J. , Velarde Esteban , Deweese Theodore L. , Drake Charles G.
Published: April 2023

Supp Figure 1. Fractionated radiotherapy (7Gy x3) of B16-OVA melanoma tumors increases the proliferation and activation of adoptively transferred OT1 T cells in the Draining Lymph Node (DLN).
Supplementary Figure 1 from Gene-Modified Human α/β-T Cells Expressing a Chimeric CD16-CD3ζ Receptor as Adoptively Transferable Effector Cells for Anticancer Monoclonal Antibody Therapy
Authors: Ochi Fumihiro , Fujiwara Hiroshi , Tanimoto Kazushi , Asai Hiroaki , Miyazaki Yukihiro , Okamoto Sachiko , Mineno Junichi , Kuzushima Kiyotaka , Shiku Hiroshi , Barrett John , Ishii Eiichi , Yasukawa Masaki
Published: April 2023

PDF file - 5868K, A. Tumor growth in mice treated with activated NK cells combined with rituximab was serially measured using in vivo bioluminescence assay. Two mice (NK-No.1* and NK-No.2**) were euthanized at different time points on day 14 and day 18, respectively. Thereafter, human NK cells and Raji cells persisting in mouse spleen and femoral bone marrow (BM) were measured by flow cytometry. B. Tumor growth in mice similarly treated with cCD16ζ-T cells and rituximab was assessed by in vivo bioluminescence assay. Experiments in Supplementary Fig. S1A and Fig. S1B were conducted in parallel. For comparison with NK-treated mice, a cCD16ζ-T-No.7# mouse was　euthanized on day 14, and cCD16ζ-T cells and Raji cells were measured similarly to those in Supplementary Fig. S1A. C. In mice treated with activated NK cells, on day 14, Raji cells were detectable at 8.0% among BM cells, but not in the spleen, as indicated by the bioluminescence assay in Supplementary Fig. S1A. Along with disease progression in Supplementary Fig. S1A from day 14 to day 18, the number of Raji cells increased from 0% to 7.4% in spleen and from 8.0% to 13.7% in BM, respectively. On the other hand, at these two time points, the relative proportion of NK cells remained constant at 4% in the spleen and 0.4% in the BM, respectively. D. Unlike mice treated with NK cells on day 14, higher numbers of effector cells were detectable (9.9% in spleen and 0.8% in BM, respectively), and no Raji cells were detected in either the spleen or BM in the cCD16ζ-T-No.7 mouse. Taken together, the data indicated that the in vivo tumor suppression mediated by cCD16ζ-T cells exploiting ADCC was superior to that mediated by NK cells.
Supplementary Figure 1 from Macropinocytosis of Nab-paclitaxel Drives Macrophage Activation in Pancreatic Cancer
Authors: Cullis Jane , Siolas Despina , Avanzi Antonina , Barui Sugata , Maitra Anirban , Bar-Sagi Dafna
Published: April 2023

Nab-paclitaxel induces M1 cytokine protein expression in vitro
Supplementary Methods from Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma
Authors: Winograd Rafael , Byrne Katelyn T. , Evans Rebecca A. , Odorizzi Pamela M. , Meyer Anders R.L. , Bajor David L. , Clendenin Cynthia , Stanger Ben Z. , Furth Emma E. , Wherry E. John , Vonderheide Robert H.
Published: April 2023

Supplementary Methods
Supplementary Figure S8 from Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma
Authors: Winograd Rafael , Byrne Katelyn T. , Evans Rebecca A. , Odorizzi Pamela M. , Meyer Anders R.L. , Bajor David L. , Clendenin Cynthia , Stanger Ben Z. , Furth Emma E. , Wherry E. John , Vonderheide Robert H.
Published: April 2023

Supplementary Figure S8. Non-tumor related events and deaths in tumor bearing C57BL/6 mice after immunotherapy.
Supplementary Figure S4 from Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma
Authors: Winograd Rafael , Byrne Katelyn T. , Evans Rebecca A. , Odorizzi Pamela M. , Meyer Anders R.L. , Bajor David L. , Clendenin Cynthia , Stanger Ben Z. , Furth Emma E. , Wherry E. John , Vonderheide Robert H.
Published: April 2023

Supplementary Figure S4. CD40 expression on APCs in subcutaneous PDA tumors.
Supplemental Figures 1 - 2 from TH2-Polarized CD4+ T Cells and Macrophages Limit Efficacy of Radiotherapy
Authors: Shiao Stephen L. , Ruffell Brian , DeNardo David G. , Faddegon Bruce A. , Park Catherine C. , Coussens Lisa M.
Published: April 2023

Supplemental Figure 1: Radiation dose response and immune profile. Supplemental Figure 2: Immune profile with RT in combination with αCSF-­1 mAb or PLX3397.
Supplementary Figure S6 from Targeting CD20+ Aggressive B-cell Non–Hodgkin Lymphoma by Anti-CD20 CAR mRNA-Modified Expanded Natural Killer Cells In Vitro and in NSG Mice
Authors: Chu Yaya , Hochberg Jessica , Yahr Ashlin , Ayello Janet , van de Ven Carmella , Barth Matthew , Czuczman Myron , Cairo Mitchell S.
Published: April 2023

Supplementary Fig.S6: The purified expanded PBNK cells have higher activating receptors expression PBNK cells were expanded ex vivo by co-culturing PBMC with irradiated geK562 feeder cell lines in the presence of 40 U/mL IL-2 for 14 days and isolated by depleting CD3+ T cells. NK cells were stained with indicated monoclonal antibodies immediately after isolation. Cell surface expression on viable cells is shown by flow cytometry analysis.
Supplementary Figure S5 from Targeting CD20+ Aggressive B-cell Non–Hodgkin Lymphoma by Anti-CD20 CAR mRNA-Modified Expanded Natural Killer Cells In Vitro and in NSG Mice
Authors: Chu Yaya , Hochberg Jessica , Yahr Ashlin , Ayello Janet , van de Ven Carmella , Barth Matthew , Czuczman Myron , Cairo Mitchell S.
Published: April 2023

Supplementary Fig.S5: exPBNK cells tracking and persistence in vivo (A) exPBNK cells were labeled with DID and iv injected into NSG mice. 8 days later after NK injection, mice were sacrificed and organs (lung, liver, spleen, kidney, heart) and bones were collected and washed with D-PBS. Fluorescent imagings were acquired and analyzed by using LIVING IMAGE (Xenogen). (B) Single cell suspensions were obtained from lung, liver and spleen and analyzed by flow cytometry to detect DID labeled exPBNK cells. (C) 1x10*7 mock exPBNK or CAR exPBNK cells were IV injected to Raji-Luc xenografted mice through the tail veins. Peripheral blood was collected at the indicated time point after NK NK injection. Circulated NK cells from mock exPBNK group and CAR exPBNK group were quantified using the Trucount method by flow cytometry analysis with anti-CD56-PE antibodies.
Supplementary Figure S4 from Targeting CD20+ Aggressive B-cell Non–Hodgkin Lymphoma by Anti-CD20 CAR mRNA-Modified Expanded Natural Killer Cells In Vitro and in NSG Mice
Authors: Chu Yaya , Hochberg Jessica , Yahr Ashlin , Ayello Janet , van de Ven Carmella , Barth Matthew , Czuczman Myron , Cairo Mitchell S.
Published: April 2023

Supplementary Fig.S4: In vitro bioluminescence to detect luciferase expression in Raji and Raji-2R cells Raji and Raji-2R cells were electroporated with ffLUCZeo-pcDNA and selected for stable clones expressing luciferase (Luc) with Zeocin. (A) The bioluminescence intensity increased proportionally with increasing Raji-Luc cell numbers. A strong correlation between number of cells and light emission was obtained (R2= 0.99). (B) The bioluminescence intensity increased proportionally with increasing Raji-2R-Luc cell numbers. A strong correlation between number of cells and light emission was obtained (R2= 0.989). (C)-(D) Dynamic change of the bioluminescent signal in Raji-Luc and Raji-2R-Luc after over 2 months selection. Signal intensities are shown as a function of time after addition of D-luciferin.
Supplementary Table 1 from Extensive Profiling of the Expression of the Indoleamine 2,3-Dioxygenase 1 Protein in Normal and Tumoral Human Tissues
Authors: Théate Ivan , van Baren Nicolas , Pilotte Luc , Moulin Pierre , Larrieu Pierre , Renauld Jean-Christophe , Hervé Caroline , Gutierrez-Roelens Ilse , Marbaix Etienne , Sempoux Christine , Van den Eynde Benoît J.
Published: April 2023

Published series of IDO1 expression assessed by immunohistochemistry in specific tumor types.
Supplementary Figures 1 through 12 from Clinical Impact of Tumor DNA Repair Expression and T-cell Infiltration in Breast Cancers
Authors: Green Andrew R. , Aleskandarany Mohammed A. , Ali Reem , Hodgson Eleanor Grace , Atabani Suha , De Souza Karen , Rakha Emad A. , Ellis Ian O. , Madhusudan Srinivasan
Published: April 2023

Supplementary Figure S1: Prognostic significance of ATM, BRCA1 and XRCC1 in breast cancers negative for CD8+ TILs. Kaplan-Meier survival curves are shown here. Supplementary Figure S2: Prognostic significance of polbeta (A & B), ERCC1 (C&D), RECQL4 (E&F), RECQL5 (G &H), BLM (I & J), PARP1 (K & L), FEN1 ( M & N), TOPO2A (O & P), Ku70/Ku80 (Q & R), Chk2 (S & T), WRN (U & V) and DNA-PKcs (W & X) in CD8+ TILs positive and CD8+ TILs negative breast cancers respectively. Kaplan-Meier survival curves are shown here. Supplementary Figure S3: Correlation between CD8 counts and ATM (A), BRCA1 (B) and XRCC1 (C). Supplementary Figure S4: Prognostic significance of ATM, BRCA1 and XRCC1 in FOXP3+ or FOXP3 negative breast cancers. Kaplan-Meier survival curves are shown here. Supplementary Figure S5: Prognostic significance of ATM, BRCA1 in PD-L1+ (tumour cells), PD-L1+ (TILs) or PD-1+ (TILs) is shown here. Kaplan-Meier survival curves are shown here. Supplementary Figure S6: Prognostic significance of ATM, BRCA1 and XRCC1 in PD-L1 negative (tumour cells), PD-L1 negative (TILs) and PD-1 negative (TILs) breast cancers. Kaplan-Meier survival curves are shown here. Supplementary Figure S7: Prognostic significance of CD8+ TILs in ER+ breast cancer [whole cohort (A), received no endocrine therapy (B) and received endocrine therapy (C)] is shown here. Supplementary Figure S8: Prognostic significance of BRCA1 (A), XRCC1 (B) or ATM (C) in CD8+ TILs positive ER+ breast cancer. Kaplan-Meier survival curves are shown here. Supplementary Figure S9: Prognostic significance of XRCC1 in CD8+/CD8- (A), PD-1+/PD-1- (B), FOXP3+/FOXP3- (C) and PD-L1+/PD-L1- (D) ER+ breast cancer that received no endocrine therapy. Supplementary Figure S10: A. Prognostic significance of XRCC1 in PD-1+/PD-1- HER2 + breast cancers. B. Prognostic significance of BRCA1 in FOXP3+/FOXP3- HER2 + breast cancers. Kaplan-Meier survival curves are shown here. Supplementary Figure S11: Prognostic significance of CD8+ TILs in ER- breast cancer [whole cohort (A), received no chemotherapy (B) and received chemotherapy (C)] is shown here. Kaplan-Meier survival curves are shown here. Supplementary Figure S12:.Prognostic significance of BRCA1 in PD-L1+/PD-L1- ER- breast cancers that received no chemotherapy. Kaplan-Meier survival curves are shown here.
Supplementary Figure Legends from Clinical Impact of Tumor DNA Repair Expression and T-cell Infiltration in Breast Cancers
Authors: Green Andrew R. , Aleskandarany Mohammed A. , Ali Reem , Hodgson Eleanor Grace , Atabani Suha , De Souza Karen , Rakha Emad A. , Ellis Ian O. , Madhusudan Srinivasan
Published: April 2023

Supplementary Figure Legends
Supplementary Figure 1 from Induced PD-L1 Expression Mediates Acquired Resistance to Agonistic Anti-CD40 Treatment
Authors: Zippelius Alfred , Schreiner Jens , Herzig Petra , Müller Philipp
Published: April 2023

Supplementary Figure 1. CD40, PD-L1, PD-1 and CTLA-4 expression.
Supplementary Figure 2 from Exome Sequencing to Predict Neoantigens in Melanoma
Authors: Pritchard Antonia L. , Burel Julie G. , Neller Michelle A. , Hayward Nicholas K. , Lopez J. Alejandro , Fatho Martina , Lennerz Volker , Wölfel Thomas , Schmidt Christopher W.
Published: April 2023

Raw data from the initial peptide screen across MLTC assessed by IFNγ ELISpot. The yellow line delineates 30 spots and the red line marks 40 spots. Each bar represents wells assessed in triplicate, averaged and the average background measurement subtracted. The top measurement was capped at 200 spots.
Supplementary Figure Legends from Efficacy of PD-1 Blockade Is Potentiated by Metformin-Induced Reduction of Tumor Hypoxia
Authors: Scharping Nicole E. , Menk Ashley V. , Whetstone Ryan D. , Zeng Xue , Delgoffe Greg M.
Published: April 2023

Supplementary figure legends.
Supplementary Figure 1 from Efficacy of PD-1 Blockade Is Potentiated by Metformin-Induced Reduction of Tumor Hypoxia
Authors: Scharping Nicole E. , Menk Ashley V. , Whetstone Ryan D. , Zeng Xue , Delgoffe Greg M.
Published: April 2023

Metformin has indirect effects on immunity in the tumor microenvironment.
Supplementary Tables S1~S2 from Phase I Study of Random Healthy Donor–Derived Allogeneic Natural Killer Cell Therapy in Patients with Malignant Lymphoma or Advanced Solid Tumors
Authors: Yang Yaewon , Lim Okjae , Kim Tae Min , Ahn Yong-Oon , Choi Hana , Chung Hyejin , Min Bokyung , Her Jung Hyun , Cho Sung Yoo , Keam Bhumsuk , Lee Se-Hoon , Kim Dong-Wan , Hwang Yu Kyeong , Heo Dae Seog
Published: April 2023

Supplementary Table S1. Demographic characteristics; Supplementary Table S2. Post-transfusion kinetics of donor NK cells in recipient peripheral blood
Fragale et al_Supplementary Fig. S2_CIR from Antitumor Effects of Epidrug/IFNα Combination Driven by Modulated Gene Signatures in Both Colorectal Cancer and Dendritic Cells
Authors: Fragale Alessandra , Romagnoli Giulia , Licursi Valerio , Buoncervello Maria , Del Vecchio Giorgia , Giuliani Caterina , Parlato Stefania , Leone Celeste , De Angelis Marta , Canini Irene , Toschi Elena , Belardelli Filippo , Negri Rodolfo , Capone Imerio , Presutti Carlo , Gabriele Lucia
Published: April 2023

Supplementary Figure 2 contains two panels with graphs of IRF8 and IRF7 overexpression cell viability in CRC cell lines transfetced with EV, WT IRF8 or 12Y IRF8 (A), or with EV and IRF7(B) and IRF8 silencing Exps (C)
Fragale et al_Supplementary Fig. S1_CIR from Antitumor Effects of Epidrug/IFNα Combination Driven by Modulated Gene Signatures in Both Colorectal Cancer and Dendritic Cells
Authors: Fragale Alessandra , Romagnoli Giulia , Licursi Valerio , Buoncervello Maria , Del Vecchio Giorgia , Giuliani Caterina , Parlato Stefania , Leone Celeste , De Angelis Marta , Canini Irene , Toschi Elena , Belardelli Filippo , Negri Rodolfo , Capone Imerio , Presutti Carlo , Gabriele Lucia
Published: April 2023

Supplementary Figure 1 contains ten panels of RT-qPCR analisis of CRC
Supplementary Data from Semaphorin4D Inhibition Improves Response to Immune-Checkpoint Blockade via Attenuation of MDSC Recruitment and Function
Authors: Clavijo Paul E. , Friedman Jay , Robbins Yvette , Moore Ellen C. , Smith Ernest , Zauderer Maurice , Evans Elizabeth E. , Allen Clint T.
Published: April 2023

Demonstrates peripheral MDSC changes, tumor effector immune cell changes and ex vivo T-cell functional data important to a thorough understanding of how Sema4D blockade alters tumor immunity.
Figure S4 from CD4+ T Cell and NK Cell Interplay Key to Regression of MHC Class Ilow Tumors upon TLR7/8 Agonist Therapy
Authors: Doorduijn Elien M. , Sluijter Marjolein , Salvatori Daniela C. , Silvestri Serenella , Maas Saskia , Arens Ramon , Ossendorp Ferry , van der Burg Sjoerd H. , van Hall Thorbald
Published: April 2023

T cell phenotype after treatment
Figure S3 from CD4+ T Cell and NK Cell Interplay Key to Regression of MHC Class Ilow Tumors upon TLR7/8 Agonist Therapy
Authors: Doorduijn Elien M. , Sluijter Marjolein , Salvatori Daniela C. , Silvestri Serenella , Maas Saskia , Arens Ramon , Ossendorp Ferry , van der Burg Sjoerd H. , van Hall Thorbald
Published: April 2023

Immune cell composition after Aldara treatment
Supplementary Figure S8. An intact adaptive immune response is necessary for efficacy triple therapy in neu/N mice. from A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice
Authors: Foote Jeremy B. , Kok Marleen , Leatherman James M. , Armstrong Todd D. , Marcinkowski Bridget C. , Ojalvo Laureen S. , Kanne David B. , Jaffee Elizabeth M. , Dubensky Thomas W. , Emens Leisha A.
Published: April 2023

(A) Tumor bearing neu/N mice were treated with isotype control (gray line) αCD4 (dashed gray line), αCD8 (dashed black line), or αCD4 + αCD8 (dotted black line) depleting antibodies. Depletion was initiated a week prior to NT2.5 tumor implantation and carried out with biweekly IP injections for the duration of the study. Depletion efficacy of 90% was confirmed before NT2.5 tumor implantation and upon completion of the study. As previously described mice were treated with IT ADU-S100 in sequence with αOX40 receptor agonistic and αPD-L1 antagonistic antibodies. Untreated tumor-bearing neu/N mice were included as control (black line). Tumor growth was followed for 35 days. (B) Serum from tumor-bearing neu/N mice receiving mock or ADU-S100 IT injection sequenced with either αOX40 receptor agonistic and αPD-L1 antagonistic antibodies or isotype matched controls was harvested 7 days post IT injection and HER-2 specific IgG antibody was measured. (C) HER-2-specific IgG antibody was measured in the cohorts of mice from figure (A) 7 days after IT-ADU-S100 injections. Statistical significance was determined through one-way Anova with significant differences in means re-evaluated using Bonferroni post-test. All data is cumulative of 2 - 3 experiments of 5 mice/group. * p < 0.05, ** p<0.01, and *** p<0.001, and **** p<0.0001.
Supplementary Figure S4. Neu/N mice are deficient in intratumoral chemokine gradients responsible for T cell trafficking. from A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice
Authors: Foote Jeremy B. , Kok Marleen , Leatherman James M. , Armstrong Todd D. , Marcinkowski Bridget C. , Ojalvo Laureen S. , Kanne David B. , Jaffee Elizabeth M. , Dubensky Thomas W. , Emens Leisha A.
Published: April 2023

In untreated, tumor bearing FVB/N and neu/N mice intratumoral chemokine gradients were evaluated by multiplex ELISA. FVB/N express increased amounts of CXCL9, CCL3, CCL4, and CCL5, whereas neu/N mice express increased amounts of CCL2. Data is representative of 3 independent experiments involving 5 mice/group. Statistical significance was determined by multiple students'' t-test and a Bonferroni-Dunn posttest was performed to correct for increasing type I error. * p < 0.05, ** p<0.01, and *** p<0.001, and **** p<0.0001.
Figure S7 from Impact of Tumor Purity on Immune Gene Expression and Clustering Analyses across Multiple Cancer Types
Authors: Rhee Je-Keun , Jung Yu Chae , Kim Kyu Ryung , Yoo Jinseon , Kim Jeeyoon , Lee Yong-Jae , Ko Yoon Ho , Lee Han Hong , Cho Byoung Chul , Kim Tae-Min
Published: April 2023

S7. The frequency of PPI gene pairs across tumor types.
Figure S2 from Impact of Tumor Purity on Immune Gene Expression and Clustering Analyses across Multiple Cancer Types
Authors: Rhee Je-Keun , Jung Yu Chae , Kim Kyu Ryung , Yoo Jinseon , Kim Jeeyoon , Lee Yong-Jae , Ko Yoon Ho , Lee Han Hong , Cho Byoung Chul , Kim Tae-Min
Published: April 2023

S2. Correlation of gene expression and tumor purity estimated from various resources.
Figure S1 from Impact of Tumor Purity on Immune Gene Expression and Clustering Analyses across Multiple Cancer Types
Authors: Rhee Je-Keun , Jung Yu Chae , Kim Kyu Ryung , Yoo Jinseon , Kim Jeeyoon , Lee Yong-Jae , Ko Yoon Ho , Lee Han Hong , Cho Byoung Chul , Kim Tae-Min
Published: April 2023

S1. The tumor purity of immune-related genes. S2.
Sup. Table 1 from Clinical Significance of Pancreatic Atrophy Induced by Immune-Checkpoint Inhibitors: A Case–Control Study
Authors: Eshet Yael , Baruch Erez Nissim , Shapira-Frommer Ronnie , Steinberg-Silman Yael , Kuznetsov Teodor , Ben-Betzalel Guy , Daher Sameh , Gluck Iris , Asher Nethanel , Apter Sara , Schachter Jacob , Bar Jair , Boursi Ben , Markel Gal
Published: April 2023

Characteristics of pancreatic atrophy patients and their matched control patients
Supplementary Tables from Phage-Based Anti-HER2 Vaccination Can Circumvent Immune Tolerance against Breast Cancer
Authors: Bartolacci Caterina , Andreani Cristina , Curcio Claudia , Occhipinti Sergio , Massaccesi Luca , Giovarelli Mirella , Galeazzi Roberta , Iezzi Manuela , Tilio Martina , Gambini Valentina , Wang Junbiao , Marchini Cristina , Amici Augusto
Published: April 2023

Tables containing detailed values for statistic analysis.
Supplementary S3 from Phage-Based Anti-HER2 Vaccination Can Circumvent Immune Tolerance against Breast Cancer
Authors: Bartolacci Caterina , Andreani Cristina , Curcio Claudia , Occhipinti Sergio , Massaccesi Luca , Giovarelli Mirella , Galeazzi Roberta , Iezzi Manuela , Tilio Martina , Gambini Valentina , Wang Junbiao , Marchini Cristina , Amici Augusto
Published: April 2023

Further characterization of immune compartments upon DNA vaccination in Î"16HER2 mice
Supplementary S2 from Phage-Based Anti-HER2 Vaccination Can Circumvent Immune Tolerance against Breast Cancer
Authors: Bartolacci Caterina , Andreani Cristina , Curcio Claudia , Occhipinti Sergio , Massaccesi Luca , Giovarelli Mirella , Galeazzi Roberta , Iezzi Manuela , Tilio Martina , Gambini Valentina , Wang Junbiao , Marchini Cristina , Amici Augusto
Published: April 2023

Generation of the LFPD Library. A Schematic representation of the wtHER2 and Î"16HER2 fragment sequences
Supplemental Table 3 from Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC
Authors: Santini Fernando C. , Rizvi Hira , Plodkowski Andrew J. , Ni Andy , Lacouture Mario E. , Gambarin-Gelwan Maya , Wilkins Olivia , Panora Elizabeth , Halpenny Darragh F. , Long Niamh M. , Kris Mark G. , Rudin Charles M. , Chaft Jamie E. , Hellmann Matthew D.
Published: April 2023

Retreatment Cohort - Recurrent irAEs: Characteristics of The Recurrent Immune-Related Toxicity
Supplemental Table 1 from Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC
Authors: Santini Fernando C. , Rizvi Hira , Plodkowski Andrew J. , Ni Andy , Lacouture Mario E. , Gambarin-Gelwan Maya , Wilkins Olivia , Panora Elizabeth , Halpenny Darragh F. , Long Niamh M. , Kris Mark G. , Rudin Charles M. , Chaft Jamie E. , Hellmann Matthew D.
Published: April 2023

Patients with Advanced NSCLC Treated at MSKCC with Immunotherapy From April 2011 to May 2016
Supplementary Data from Regulatory T Cells in an Endogenous Mouse Lymphoma Recognize Specific Antigen Peptides and Contribute to Immune Escape
Authors: Ahmetlić Fatima , Riedel Tanja , Hömberg Nadine , Bauer Vera , Trautwein Nico , Geishauser Albert , Sparwasser Tim , Stevanović Stefan , Röcken Martin , Mocikat Ralph
Published: April 2023

Supplementary figures and table
Supplementary Data File from Early-Life Microbiota Exposure Restricts Myeloid-Derived Suppressor Cell–Driven Colonic Tumorigenesis
Authors: Harusato Akihito , Viennois Emilie , Etienne-Mesmin Lucie , Matsuyama Shingo , Abo Hirohito , Osuka Satoru , Lukacs Nicholas W. , Naito Yuji , Itoh Yoshito , Li Jian-Dong , Merlin Didier , Gewirtz Andrew T. , Denning Timothy L.
Published: April 2023

Complete Supplementary Data File
Supplementary Figures 1-6 from A High-Throughput Immune-Oncology Screen Identifies EGFR Inhibitors as Potent Enhancers of Antigen-Specific Cytotoxic T-lymphocyte Tumor Cell Killing
Authors: Lizotte Patrick H. , Hong Ruey-Long , Luster Troy A. , Cavanaugh Megan E. , Taus Luke J. , Wang Stephen , Dhaneshwar Abha , Mayman Naomi , Yang Aaron , Kulkarni Meghana , Badalucco Lauren , Fitzpatrick Erica , Kao Hsiang-Fong , Kuraguchi Mari , Bittinger Mark , Kirschmeier Paul T. , Gray Nathanael S. , Barbie David A. , Jänne Pasi A.
Published: April 2023

Suppl. Fig. 1-6
Supplementary Data from A Synthetic DNA, Multi-Neoantigen Vaccine Drives Predominately MHC Class I CD8+ T-cell Responses, Impacting Tumor Challenge
Authors: Duperret Elizabeth K. , Perales-Puchalt Alfredo , Stoltz Regina , G.H. Hiranjith , Mandloi Nitin , Barlow James , Chaudhuri Amitabha , Sardesai Niranjan Y. , Weiner David B.
Published: April 2023

TC1, LLC and ID8 neoantigen list
Figure S5 from Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity
Authors: Ager Casey R. , Reilley Matthew J. , Nicholas Courtney , Bartkowiak Todd , Jaiswal Ashvin R. , Curran Michael A.
Published: April 2023

Asymmetric TRAMP-C2 tumor growth kinetics
Figure S1 from Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity
Authors: Ager Casey R. , Reilley Matthew J. , Nicholas Courtney , Bartkowiak Todd , Jaiswal Ashvin R. , Curran Michael A.
Published: April 2023

Flow cytometry antibody catalog